Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549

详细信息    查看全文

• 作者：Wei Zhang (1)
  Jing Zhu (1)
  Jing Bai (1)
  Hui Jiang (1)
  Fangli Liu (1)
  An Liu (1)
  Peng Liu (1)
  Guohua Ji (1)
  Rongwei Guan (1)
  Donglin Sun (1)
  Wei Ji (1)
  Yang Yu (1)
  Yan Jin (1) (2)
  Xiangning Meng (1)
  Songbin Fu (1)
  
• 刊名：Journal of Experimental & Clinical Cancer Research
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：29
• 期：1
• 全文大小：1195KB
• 参考文献：1. Michalides RJ: Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. / J Clin Pathol 1999,52(8):555-68. CrossRef
  2. Park MT, Lee SJ: Cell cycle and cancer. / J Biochem Mol Biol 2003,36(1):60-5.
  3. Sharpless NE: INK4a/ARF: a multifunctional tumor suppressor locus. / Mutat Res 2005,576(1-):22-8.
  4. Robertson KD, Jones PA: Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. / Oncogene 1999,18(26):3810-820. CrossRef
  5. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST, Lee JC, Huang DP: Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. / Br J Cancer 1999,81(7):1122-126. CrossRef
  6. Ivanchuk SM, Mondal S, Dirks PB, Rutka JT: The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. / J Neurooncol 2001,51(3):219-29. CrossRef
  7. Wei W, Hemmer RM, Sedivy JM: Role of p14(ARF) in replicative and induced senescence of human fibroblasts. / Mol Cell Biol 2001,21(20):6748-757. CrossRef
  8. Kaelin WG Jr: The emerging p53 gene family. / J Natl Cancer Inst 1999,91(7):594-98. CrossRef
  9. Kawamoto K, Enokida H, Gotanda T, Kubo H, Nishiyama K, Kawahara M, Nakagawa M: p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. / Biochem Biophys Res Commun 2006,339(3):790-96. CrossRef
  10. Lee M, Sup Han W, Kyoung Kim O, Hee Sung S, Sun Cho M, Lee SN, Koo H: Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. / Pathol Res Pract 2006,202(6):415-24. CrossRef
  11. Almeida LO, Custodio AC, Araujo JJ, Rey JA, Almeida JR, Santos MJ, Clara CA, Casartelli C: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors. / Genet Mol Res 2008,7(2):451-59. CrossRef
  12. Pacifico A, Goldberg LH, Peris K, Chimenti S, Leone G, Ananthaswamy HN: Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers. / Br J Dermatol 2008,158(2):291-97. CrossRef
  13. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. / Science 1994,264(5157):436-40. CrossRef
  14. Park MJ, Shimizu K, Nakano T, Park YB, Kohno T, Tani M, Yokota J: Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. / Cancer Genet Cytogenet 2003,141(1):5-3. CrossRef
  15. Zhang X, Jin Y, Tao X, Bai M: Effects of exogenous p16(ink4a) gene on biological behaviors of human lung cancer cells. / J Huazhong Univ Sci Technolog Med Sci 2007,27(1):37-0. CrossRef
  16. Fang K, Chiu CC, Li CH, Chang YT, Hwang HT: Cisplatin-induced senescence and growth inhibition in human non-small cell lung cancer cells with ectopic transfer of p16INK4a. / Oncol Res 2007,16(10):479-88. CrossRef
  17. Xie QC, Hu YD, Wang LL, Chen ZT, Diao XW, Wang ZX, Guan HJ, Zhu B, Sun JG, Duan YZ, Chen FL, Nian WQ: The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity. / Colloids Surf B Biointerfaces 2005,46(3):188-96. CrossRef
  18. Yang G, Rajadurai A, Tsao H: Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. / J Invest Dermatol 2005,125(6):1242-251. CrossRef
  19. Matsui H, Tomizawa K, Lu YF, Matsushita M: Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. / Curr Protein Pept Sci 2003,4(2):151-57. CrossRef
  20. Ohta Y, Kamiya T, Nagai M, Nagata T, Morimoto N, Miyazaki K, Murakami T, Kurata T, Takehisa Y, Ikeda Y, Asoh S, Ohta S, Abe K: Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. / J Neurosci Res 2008,86(13):3028-037. CrossRef
  21. Ju KL, Manley NC, Sapolsky RM: Anti-apoptotic therapy with a Tat fusion protein protects against excitotoxic insults in vitro and in vivo. / Exp Neurol 2008,210(2):602-07. CrossRef
  22. Gao N, Hu YD, Cao XY, Zhou J, Cao SL: The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. / J Cancer Res Clin Oncol 2001,127(6):359-67. CrossRef
  23. Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P, Cowan K: Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. / Oncogene 1998,16(2):265-72. CrossRef
  24. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. / Cancer Res 1995,55(6):1351-354.
  25. Bai-qiu W, Cheng-hui Y, Hui G, Song-bin F, Pu L: Growth inhibition of transfection of p16 gene to lung adenocarcinoma cell lines Anip973 and AGZY83-a. / Chin J Lung Cancer 2001.,4(6):
  26. Yi-zhao C, Rui-xiang X, Shi-zhong Z, Ling Z: Different effects of p16 gene on human glioma cell lines through different transfection methods. / Ai Zheng 2000,19(2):116-20.
  27. Harbour JW, Worley L, Ma D, Cohen M: Transducible peptide therapy for uveal melanoma and retinoblastoma. / Arch Ophthalmol 2002,120(10):1341-346.
  28. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. / Science 1999,285(5433):1569-572. CrossRef
  29. Sun J, Yan Y, Wang XT, Liu XW, Peng DJ, Wang M, Tian J, Zong YQ, Zhang YH, Noteborn MH, Qu S: PTD4-apoptin protein therapy inhibits tumor growth in vivo. / Int J Cancer 2009,124(12):2973-981. CrossRef
  
• 作者单位：Wei Zhang (1)
  Jing Zhu (1)
  Jing Bai (1)
  Hui Jiang (1)
  Fangli Liu (1)
  An Liu (1)
  Peng Liu (1)
  Guohua Ji (1)
  Rongwei Guan (1)
  Donglin Sun (1)
  Wei Ji (1)
  Yang Yu (1)
  Yan Jin (1) (2)
  Xiangning Meng (1)
  Songbin Fu (1)
  
  1. Laboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China
  2. Key Laboratory of Medical Genetics (Harbin Medical University), Heilongjiang Higher Education Institutions, Harbin, 150081, China
  
• ISSN：1756-9966

文摘

Background The tumor suppressor gene CDKN2A generates at least three different transcriptional variants, each of which is thought to encode a tumor suppressor. However, the inhibitory activities of these variants have not yet been compared in the same cells. Protein therapy is known to have several advantages over gene therapy. Thus, investigation of the exogenous protein molecule of the most effective suppressor may yield meaningful information regarding protein-based cancer therapy. Methods The inhibitory effects of p16INK4a, p14ARF and p12 were studied in the human lung cancer cell line A549 which lacks the CDKN2A locus. The eukaryotic expression plasmids of the three transcriptional variants were constructed and stably transfected into the cells. RNA and protein expression by the plasmids was confirmed using RT-PCR and fluorescence immunocytochemistry, respectively. Cell growth inhibition and cell-cycle redistribution after transfection were investigated based on growth curve and flow cytometry analyses. An exogenous His-tag fusion p16INK4a protein was obtained and purified by affinity chromatography. Cell growth inhibition and cell cycle arrest induced by the expression of p16INK4a protein were measured in A549 cells transduced with the exogenous protein. Results While all three variants suppressed cell growth, p16INK4a had the strongest effect. Marked G1-phase accumulation and S-phase inhibition were induced by p16INK4a and p14ARF but not by p12. Exogenous p16INK4a protein was successfully expressed and purified and transduction of the fusion protein into A549 cells inhibited cell growth by G1→S arrest. Conclusions Among the three transcript variants, p16INK4a has a greater inhibitory effect than p14ARF and p12; exogenous p16INK4a protein should be further investigated for use in cancer therapy as a protein agent.